Post-transcriptional regulation by miRNAs is essential for complex molecular responses to physiological insult and disease. Although many disease-associated miRNAs are known, their global targets and culminating network effects on pathophysiology remain poorly understood. We applied AGO CLIP to systematically elucidate altered miRNAtarget interactions in brain following ischemia/reperfusion (I/R) injury. Among 1,190 identified, most prominent was the cumulative loss of target regulation by miR-29 family members. Integration of translational and time-course RNA profiles revealed a dynamic mode of miR-29 target de-regulation, led by acute translational activation and later increase in RNA levels, allowing rapid proteomic changes to take effect. These functional regulatory events rely on canonical and non-canonical miR-29 binding and engage glutamate reuptake signals to control local glutamate levels. These results uncover a miRNA target network that acts acutely to maintain brain homeostasis after ischemic stroke.
INTRODUCTION
Divergent post-transcriptional gene regulation in the brain is indispensable to achieve its highly specialized and diverse functions. An aspect of this control is mediated by miRNAs, small non-coding RNAs that fine-tune gene expression by base pairing to 3'UTRs for target mRNA repression (Baek et al., 2008; Bartel, 2009 ). A single miRNA can have multiple targets, providing coordinate governance over a network of genes.
Their dynamic regulatory capacity, including precise temporal responses to external cues (Ebert and Sharp, 2012 ) and spatial-specific targeting of localized mRNAs (Leung and Sharp, 2006) provide an elegant molecular solution to meet the brain's unique physiological demands. Ablation of the miRNA processing machinery, Dicer, leads to neuronal loss, memory/behavior deficits, neurodegenerative phenotypes akin to Parkinson's Disease (PD) and even enhancement of poly-glutamine toxicity (Bilen et al., 2006; Kim et al., 2007) . Although substantial research has determined a requirement of miRNAs for proper function, the identities, targets, and collective roles of their regulatory network in disease remain largely unknown.
The development of high-throughput approaches to capture and identify cellular RNAs has catapulted the search for miRNA regulatory networks. These unbiased, highly sensitive and quantitative technologies have been especially useful for identifying miRNAs with divergent expression patterns in dynamic physiologic contexts and in disease. However, many studies are limited by their inability to define precise gene regulatory networks impacted by altered miRNA expression. HITS-CLIP (highthroughput sequencing of RNAs isolated by crosslinking immunoprecipitation) combines rigorous biochemical methods with hi-throughput sequencing technology to identify bona fide RNA:protein interactions (Licatalosi et al., 2008) . When applied with RNA- Stroke is a major cause of death and disability worldwide, with limited therapeutic options (Moskowitz et al, 2010) . The molecular pathology of ischemic stroke is poorly understood, particularly the early gene expression changes and regulatory events that mediate neuro-protection and ischemic cell death (Moskowitz et al., 2010, Iadecola and Anrather, 2011) . In the present study we employed AGO CLIP for transcriptome-wide mapping of altered miRNA targeting events in an I/R injury model of stroke. Differential profiling of AGO bound RNA distinguished over one thousand miRNA:mRNA events changing in stroke. Detailing the global molecular events lead by a single family of robustly down-regulated miRNAs, miR-29s, unveiled a dynamic and coordinate cascade of target activation, impacting mRNA translation at an early time-point, followed by a global increase in steady-state RNA levels. Unexpectedly, many of the functional miRNA binding events relied on non-canonical seed pairing events, underscoring the importance of empirically identified targets over informatic predictions. We extend these findings to provide new insights to the network of stroke-miRNA targets mediating glutamate homeostasis and to miRNA regulatory site polymorphisms as potential determinants of disease outcome, providing novel insights and strategy toward understanding human stroke disease.
RESULTS

Identification of AGO:RNA interactions in stroke response
To model human ischemic stroke, we used the mouse middle cerebral artery occlusion (MCAo) model ( Figure 1A ). This procedure relies on the transient occlusion of the middle cerebral artery (MCA), the artery most often occluded in stroke patients, and further model the molecular events of reperfusion that follow (Casals et al., 2011). For CLIP, we chose an early time-point of 3hrs (post I/R injury) in order to distinguish direct molecular consequences of stroke injury from indirect events involving secondary phenomena such as major cell death and infiltration of blood-borne inflammatory cells (Iadecola and Anrather, 2011).
For differential analysis of AGO-associated RNA, we compared data from 'Stroke' hemisphere, containing the ischemic territory, to the contralateral 'Control' hemisphere ( Figure 1A ). Sham surgery animals were also assessed to rule out general affects caused by surgical anesthesia ( Figure S1A ). We focused our biochemical analysis on cortical tissues surrounding the center of the ischemic territory (ischemic core), the "ischemic periphery," a region at risk for infarction targeted by intrinsic neuro-protective mechanisms ( Figure 1A throughput sequencing and mapped to the mouse reference genome for AGO:mRNA binding peak definition, using a previously reported peak calling strategy (Chi et al., 2009 , Moore et al., 2014 , and to the miRBase reference of miRNAs for AGO-bound miRNA assessment (Kozomara and Griffiths-Jones, 2010).
Quantitative analysis of binding peaks, using peak height measurements (sequence read per peak) was performed to reveal stroke-specific AGO binding patterns ( Figure   1B ). CLIP reads across 4-5 biological replicates had high correlations (average Pearson correlation coefficients of ~0.7 to 0.9 for miRNAs, and of ~0.6 for mRNAs (Figure S1C-D). Analysis of binding events reproducible in at least 3 replicates for a single condition (biological complexity, BC3 or greater) (Moore et al., 2014) identified 123 miRNAs with significantly altered AGO association in stroke (p<0.05) of which 61 showed an increase while 62 were decreased ( Figure 1C ), while those identified in Sham condition showed minimal resemblance ( Figure S1E ). miRNAs with altered AGO binding included many that have been previously implicated in stroke, such as miR-30d, miR-26b, miR-16, miR-222, and miR-183. The most notable changes were observed among the three members of the miR-29 family, miR-29a, -29b, and -29c ( Figure 1C ).
For the investigation of AGO-bound mRNAs, CLIP peaks were assigned a binding region of 80 nt widths relative to peak midpoints, slightly wider than previously defined peak width (Chi et al., 2009 ). Only peaks containing reads from 3 out of 5 biological replicates were considered (BC≥3). Using this approach, we identified 18, 285 reproducible AGO peaks, out of which 1,190 were differentially bound by AGO in stroke condition (determined by binomial testing and applying p-value cut off, p<0.05). Among these 'stroke peaks', 430 showed increased binding while 760 showed a significant decrease ( Figure 1D ). Although canonical miRNA targeting is at the 3'UTRs of mRNAs, previous CLIP studies have shown miRNA guided AGO targeting also occurs within coding sequences, 5'UTRs and in introns (Chi et al., 2009 , Moore et al., 2014 . To assess whether the transcriptome-wide sites of AGO targeting is altered upon I/R injury, we determined the distribution of 1,190 stroke peaks among annotated transcript regions. As expected, the majority (45%) of stroke peaks reside within annotated 3'UTR regions, while a smaller portion found in introns (29%) and coding regions (18%).
We saw no difference in the genomic distribution of stroke peaks with respect to 'all' 6 AGO binding events ( Figure 1E ). The proportion of 3'UTR peaks was higher (49%) when indeterminate binding events, also identified in 'Sham' condition, were removed from analysis (Figure S1F-G). Finally, we performed 6-nucleotide motif enrichment analysis of stroke peaks, among up-and down-regulated peaks within 3'UTRs, independently ( Figure 1F ). Strikingly, 6mer seed motif engaging miR-29 binding was the top enriched motif among down-regulated stroke peaks. Global AGO regulatory site mapping of miRNA and mRNA collectively suggest a role for miR-29 dysregulation in stroke brain. . Cumulative distribution function (CDF) plots of CLIP fold changes showed a significant global reduction in AGO binding to miR-29 sites, while collective binding to highly abundant brain miRNA ('top 10') sites and to let-7 sites showed similar distribution as background or 'all' sites ( Figure 2C ). CLIP binding changes across sham and control comparison showed similar distribution for all sites, suggesting down-regulation of miR-29 targets is specific to I/R injury ( Figure 2D ). These data demonstrate a collective loss of regulation at transcriptome-wide miR-29 target sites following acute I/R injury.
Acute de-repression of miR-29 targets occurs mainly by translational activation
To assess the functional molecular consequence resulting from global de-regulation at miR-29 sites, we measured steady-state mRNA levels by RNAseq at identical acute 
RNA levels of miR-29 targets increase at later stages following stroke
The cellular response to I/R injury is a complicated and dynamic process, involving many factors that generate influence at various times after reperfusion. We asked whether down-regulation of miR-29 and the concomitant activation of its targets are restricted to the initial acute phase following injury. For this, we examined the cortical transcriptome at additional reperfusion time-points (6, 12, and 24hrs after I/R) to generate a time-course miRNA and mRNA profiles ( Figure 3A ). Time-dependent miRNAseq revealed that miR-29 loss is persistent through 24hrs following I/R. This was true for all three miR-29 family members, while let-7a showed no consistent changes 
miR-29 target recognition relies on canonical and non-canonical sites
To determine whether miR-29 loss directly activate miR-29 targets, we employed an established in vitro system for cerebral ischemic injury. Cultured mouse cortical cells (consisting of ~70% cortical neurons, ~30% astrocytes) were exposed to oxygenglucose deprivation (OGD). After OGD, the cultures were replenished with full growth media and re-oxygenated to simulate reperfusion. This culture system allows for direct quantification of gene expression and is accessible for loss/gain of function studies Therefore we compared the function consequences of miR-29 targets defined by TargetScan predicted canonical seed matched sites (7-8mer pairing, highly conserved) and to sites defined exclusively by AGO CLEAR-CLIP (canonical and non-canonical seed matched sites disregarded by computational prediction). CLEAR-CLIP defined miR-29 targets showed greater activation in response to OGD than targets predicted by TargetScan alone ( Figure 4C ). Further delineation of CLEAR-CLIP defined miR-29 seed types revealed that the greatest response was among targets with 7-8mer seeds and, unexpectedly, among targets containing non-canonical seed sites ( Figure 4D ), while 6mer seed targets showed moderate response. These observations suggest a critical role for non-canonical miRNA targets in response to I/R injury and underscore the necessity for both computational and empirical methods to define RNA regulatory networks within relevant physiological systems.
In order to address the requirement for miR-29 loss in target activation, we relied on a gain-of-function experiment using lentiviral gene delivery to over-express miR-29.
Quantitative PCR of lentivirus infected cortical cultures showed effective restoration of OGD dependent miR-29 down-regulation ( Figure 4E ). Accordingly, RNAseq profiles revealed that this restoration was sufficient to suppress global miR-29 target activation ( Figure 4F ). The loss of miR-29 is a necessary event for the global activation of its targets, as restoration of miR-29 abolishes its transcriptome-wide impact.
Activated miR-29 targets are enriched in glial genes and activate a regulatory network governing glutamate signaling
In the brain, miR-29 is predominantly expressed by astrocytes, with moderate levels detected in neurons (Smirnova et al., 2005) , suggesting a major role for miR-29 in regulating astrocyte physiology. Therefore, we examined miR-29 targets whose expression is also restricted to astrocytes. We ranked our down-regulated AGO peaks by their relative enrichment in astrocytes, using a published reference for brain cell-type transcriptomes (Zhang et al., 2014) ( Figure 5A ). The top astrocytic miR-29 targets included aquaporin 4 (AQP4; gene symbol: Aqp4), known to play a key role in water balance, edema, blood brain barrier permeability and subsequent neuroinflammation in stroke (Fukuda and Badaut, 2012) , VEGF, (vascular endothelial growth factor; gene symbol: Vegfa) an early hypoxic responder regulating cerebral edema similar to AQP4, switching to promote neurogenesis and vascular repair during later phases (Greenberg and Jin, 2013) , and glial mediators of glutamate signaling: mGluR3 (metabotropic glutamate receptor type 3; gene symbol: Grm3) and GLT-1 (glial high affinity glutamate transporter, gene symbol: Slc1a2). The identification of key astrocytic genes suggests miR-29 targets' critical brain homeostatic role in responding to I/R injury.
We also performed pathway enrichment analysis for CLIP defined, de-regulated miR- Akt3) and GSK (gene symbol: Gsk3b). We also included Aqp4 and Vegfa, miR-29 targets and established stroke response genes, in our assessment. Genome visualization of stroke AGO CLIP data showed significant decrease in respective 3'UTR peaks at corresponding miR-29 sites for all representative genes ( Figure 5C ).
Quantitative expression analysis of demonstrated RNA accumulation in OGD and most importantly, miR-29 over-expression repressed induced RNA levels to near baseline for 6 out of 7 genes ( Figure 5D ). Moreover, quantitative assessment of selected glial factors, GLT-1, mGluR3, AQP4 and VEGF, confirmed their increase in steady-state protein levels within cortical stroke tissues early (3hr) upon I/R injury ( Figure 5E, S4C) .
Taken together, the data reveal an acutely activated miRNA target network in response to anoxic depolarization and excess glutamate. Responsive miR-29 targets respond to glutamate signals by engaging post-synaptic and glial-specific glutamate receptors (GluR3 and mGluR3), in addition to downstream signaling effectors (AKT3 and GSK).
Remarkably, a critical glial factor for uptake of excess glutamate (GLT-1) is also involved, indicating an effort to counteract excitoxicity and to restore brain glutamate homeostasis ( Figure 5F ).
miR-29 regulated reuptake signal controls brain glutamate levels
GLT-1 (excitatory amino acid transporter 2, EAAT2) is a major glutamate transporter in the brain, playing critical roles in buffering glutamate levels. We further investigated the role of miR-29:GLT-1 regulatory axis in mediating glutamate homeostatic functions in I/R injury. Interestingly, the AGO down-regulated miR-29 site on GLT-1 3'UTR does not contain canonical seed matched sequence. We therefore tested the functionality of this site by design of a target site blocker (TSB) to CLIP defined 20nt AGO binding region ( Figure 5C, Slc1a2) . As expected, miR-29 over-expression in OGD cultures (+control TSB) repressed OGD dependent accumulation of GLT-1 RNA, however, TSB against miR-29 binding site of GLT-1 3'UTR abrogated miR-29 repression to near baseline levels, as GLT-1 RNA levels were similarly induced as in OGD without miRNA overexpression ( Figure 6A ). This suggests that precise 3'UTR recognition by miR-29 is required for GLT-1 RNA regulation in OGD. To determine if miR-29:GLT-1 interaction has an effect on GLT-1's ability to uptake extracellular glutamate, we quantified glutamate concentrations in OGD culture media in presence or absence of miR-29 and TSB ( Figure 6B ). OGD stimulus readily increased glutamate levels in media, and overexpression of miR-29 by lentiviral gene delivery exacerbated this induction. Intriguingly, site-specific inhibition of miR-29:GLT-1 by TSB counteracted the miR-29 dependent glutamate accumulation ( Figure 6C ). The data suggests miR-29 de-regulation and responsive activation of GLT-1 may play a role in cellular glutamate regulation by promoting uptake of toxic glutamate in response to I/R injury.
We took this investigation further, to demonstrate in vivo evidence of miR-29 control on GLT-1 and glutamate in stroke animals. Local GLT-1 protein levels in cortical tissue surrounding ischemic territory are robustly up-regulated upon stroke (3hrs post I/R), suggesting localized activation of glutamate re-uptake signal ( Figure 6D ). Proton magnetic resonance spectroscopy ( 1 H-MRS) is a non-invasive clinical approach to monitor and quantify levels of brain metabolites altered in disease (Ramadan et al., 2013) . We leveraged this technology to assess brain glutamate levels in stroke MCAo animals. 1 H-MRS spectra reliably measured brain glutamate associated Glx peak, resonating between 2.2-2.6ppm ( Figure S5A ). Data acquisition for each 1 H-MRS scan requires a precise placement of a 2mm cubic voxel at a localized region of interest.
Hence, we relied on T2 MRI acquired images of ischemic territory to appropriately focus our measurements near I/R damaged regions ( Figure 6E ). Using this method, we successfully detected a significant induction of brain glutamate in stroke hemisphere compared to control ( Figure 6F-G) . For testing miR-29 regulated glutamate in I/R injured brain, we engineered adeno-associated virus (AAV) to deliver miR-29 by stereotaxic injections. MCAo surgery was then performed on injected animals for assessment by MRI/MRS ( Figure 6H ). GFP reporter encoding AAV was successfully delivered within desired brain region ( Figure S5B ). In addition, by using an AAV serotype characterized for preferential infection of astrocytes, AAV8 (Aschauer et al., 2013), we were able to effectively target gene delivery to glia, allowing a robust signal to noise assessment of astrocyte-specific GLT-1 ( Figure S5C ). We also confirmed miR-29 regulation of GLT-1 in cortical stroke tissue, as AAV8-miR-29 robustly silenced GLT-1, while scramble control virus had no effect ( Figure 6I-J) . Remarkably, 1 H-MRS measurements revealed a significant increase in brain glutamate levels animals injected with AAV-miR29 over scrambled controls ( Figure 6K ). This observation was exclusive to early times (2-4hr) upon I/R. At a later time (24hr) we detected extremely high levels of glutamate in both control and in treated animals and saw no effects with AAV-miR29 pre-treatment. Thus activated GLT-1 is sufficient for attenuating glutamate levels early upon injury, however, not a later time when excitotoxic effects reach overwhelming levels. This temporal dynamic of stroke brain glutamate levels reflects our global observation of miR-29 target activation (main Figures 2-3) . Acute post-transcriptional effects dominate early molecular responses and govern immediate physiological outcomes such as glutamate control. While later consequences mediated by increase in target RNAs may facilitate secondary and chronic responses to I/R insult. Collectively, these results serve as strong in vitro and in vivo evidence for an activated miRNA target facilitating homeostatic control in I/R injured brain.
Identification of human genetic polymorphisms in stroke-associated miR-29 sites
To apply our findings from animal model system to human stroke, we generated human brain AGO CLIP data to define orthologous, stroke-associated, human miRNA regulatory sites. For human CLIP, we used post-mortem medial prefrontal cortex tissues from 6 individuals. To further increase biological complexity for robust peak calling, we merged our in-house generated data with a human AGO CLIP resource (Boudreau et al., 2014) generated from motor cortex and cingulate gyrus of 17 individuals. Together, these data defined 23,662 reproducible (peak height >50) human AGO brain peaks.
Intersecting these sites to mouse stroke peaks (999 Hg19 mapped out of 1, 190) identified 429 orthologous AGO regulatory sites ( Figure 7A ). Peak evaluation and motif analysis revealed human brain enriched miRNAs ( Figure 7B . We implemented an informatic analysis to identify single nucleotide polymorphisms within the 429 stoke-associated miRNA sites. We relied on existing SNPs previously submitted to NCBI's dbSNP resource and intersected them with 7-8mer seed containing, miRNA binding sites within our 429 cohort. We identified 332 unique single nucleotide variations among 165 sites representing 222 miRNAs across 117 genes ( Supplementary Table 5 ). Notably, we identified 6 SNPs that modify miR-29 target sequences. The alternative alleles among these 6 sites represent both rare and common variants within the human population. 5 out of the 6 variants have the potential to disrupt miR-29 binding, while 1 may enhance miR-29 seed pairing (Figure 7C, S6) .
Some reside within a single 3'UTR polymorphisms for two distinct miR-29 binding sites (rs147077348 and rs574793836, SPARC 3'UTR), and others alter divergent nucleotides within a single miR-29 seed binding sequence (rs191276899 and rs757907139, WASF1 3'UTR). Interestingly, we identified a SNP within a known stroke response gene (rs760955838, AQP4 3'UTR). rs760955838 is a rare variant, the alternative allele (A) indicating a lower predicted binding energy coefficient than reference allele (G), thus may weaken miR-29 seed pairing and affect AQP4 gene expression ( Figure 7D ). This study illustrates a unique approach to investigate disease relevant polymorphisms altering RNA regulatory functions and may provide useful genetic resource for better understanding clinical stroke outcomes.
DISCUSSION
Empirical investigation of unique biological and pathological states is imperative for elucidating mechanisms underlying relevant physiology. AGO CLIP affords the power to systemically identify and quantify miRNA:target interactions in normal and disease brain, prevailing informatic predictions. In this study, AGO-CLIP allowed us to discover acutely activated network of miRNA targets due to a de-regulated miR-29 in I/R injury.
The dynamic molecular mode of global activation is led by a strong translational effect with minimal impact on mRNA levels. Such temporally precise regulatory action of miRNA, limited to distinct physiological circumstances have been similarly described in We uncovered a novel regulatory network of miR-29 targets facilitating key astrocytic functions to regain homeostatic control upon I/R injury, including maintenance of blood brain barrier and glutamate signaling. Astrocytes play a central role in brain homeostasis, particularly via cooperative processes they establish with neurons to supply energy metabolites, mediate neurotransmitter action, and regulate water and ion concentrations (Phatnani and Maniatis, 2015) . We find astrocytic miR-29 targets, along with few neuronal targets, engage glutamate signaling in a consorted effort to buffer toxic glutamate levels, as altering miR-29 levels effect brain glutamate accumulation.
We find that this is in part due to miR-29 specific regulation of GLT-1 (EAAT2), a glialspecific glutamate transporter that control glutamate levels by its rapid uptake from 
